Skip to main content
SpringerLink
Log in

Practical Gastrointestinal Oncology Correlative Science

  • Chapter
  • First Online:
Gastrointestinal Oncology

  • 1659 Accesses

Abstract

Gastrointestinal (GI) cancers, like other human malignancies, are characterized by the accumulation of a variety of genetic alterations, including mutations that lead to inactivation of tumor suppressor genes or activation of oncogenes. These genetic and epigenetic changes can be used to classify tumors on the molecular level, and form the basis for development of new prognostic and predictive markers. While a number of molecular prognostic factors in GI cancers have been recognized or postulated (Table 3.1), few have been validated in large data sets to date and their utilization is not yet considered a standard of care. The essential prognostic factors for carcinomas across all GI sites remain the anatomic stage as classified, using TNM categories, lymphovascular invasion, and achievement of margin-negative surgical resection in potentially curable neoplasms. However, with the development of therapies targeted to specific molecular pathways involved in tumorigenesis, characterization of molecular alterations in individual GI malignancies has become important for prediction of response to therapy and thus may be used in some situations to guide selection of treatment options. Currently, the two most prominent examples are colorectal carcinoma and gastrointestinal stromal tumors (GISTs), for which molecular testing for prediction of response to therapy has become widely applied in certain clinical settings, such as KRAS mutational testing prior to treatment with cetuximab in high stage colorectal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A et al (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31:113–120

    PubMed  Google Scholar 

  • Alexander J, Watanabe T, Wu T-T, Rashid A, Li S, Hamilton SR (2001) Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158:527–535

    CAS  PubMed  Google Scholar 

  • Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P et al (2002) Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735–1743

    CAS  PubMed  Google Scholar 

  • Amado RG, Wolf M, Peters M, Van CE, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    CAS  PubMed  Google Scholar 

  • Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG (2005) NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29:1170–1176

    PubMed  Google Scholar 

  • Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ et al (2001) Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85:692–696

    CAS  PubMed  Google Scholar 

  • Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182–4190

    CAS  PubMed  Google Scholar 

  • Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C et al (2001) Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92:657–662

    CAS  PubMed  Google Scholar 

  • Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M et al (2005) Microsatellite instability and colorectal cancer prognosis [see comment] [erratum appears in Clin Cancer Res 2006 Jun 15;12(12):3868–3869]. Clin Cancer Res 11:8332–8340

    CAS  PubMed  Google Scholar 

  • Benjamin RS, Rankin C, Fletcher C, Blanke C, Von Mehren M, Maki R et al; for the Sarcoma Intergroup (2003) Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 22:814

    Google Scholar 

  • Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F et al (2008) A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6:206–214

    CAS  PubMed  Google Scholar 

  • Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J, Bisgaard ML et al (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3:121–125

    CAS  PubMed  Google Scholar 

  • Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH (1991) Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 10:4121–4128

    CAS  PubMed  Google Scholar 

  • Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J et al (2008) KRAS status and efficiency of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 26:178s

    Google Scholar 

  • Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257

    CAS  PubMed  Google Scholar 

  • Brainard JA, Goldblum JR (1997) Stromal tumors of the jejunum and ileum: a clinicopathologic study of 39 cases. Am J Surg Pathol 21:407–416

    CAS  PubMed  Google Scholar 

  • Brueckl WM, Heinze E, Milsmann C, Wein A, Koebnick C, Jung A et al (2004) Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett 203:181–190

    CAS  PubMed  Google Scholar 

  • Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145

    CAS  PubMed  Google Scholar 

  • Carballo M, Roig I, Aguilar F, Pol MA, Gamundi MJ, Hernan I et al (2005) Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 132:361–364

    PubMed  Google Scholar 

  • Carney JA (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74:543–552

    CAS  PubMed  Google Scholar 

  • Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R (2003) Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 23:3067–3078

    CAS  PubMed  Google Scholar 

  • Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W et al (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64:5913–5919

    CAS  PubMed  Google Scholar 

  • Choi SW, Lee KJ, Bae YA, Min KO, Kwon MS, Kim KM et al (2002) Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 8:2311–2322

    CAS  PubMed  Google Scholar 

  • Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T et al (2004) PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 126:318–321

    CAS  PubMed  Google Scholar 

  • Conlin A, Smith G, Carey FA, Wolf CR, Steele RJC (2005) The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54:1283–1286

    CAS  PubMed  Google Scholar 

  • Corless CL, McGreevey L, Haley A, Town A, Heinrich MC (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567–1572

    CAS  PubMed  Google Scholar 

  • Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825

    CAS  PubMed  Google Scholar 

  • Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M et al (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689–695

    CAS  PubMed  Google Scholar 

  • Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N et al (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128:270–279

    CAS  PubMed  Google Scholar 

  • Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093–1103

    CAS  PubMed  Google Scholar 

  • DeMatteo RP, Lewis JJ, Leung D, Mundan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    CAS  PubMed  Google Scholar 

  • Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104

    CAS  PubMed  Google Scholar 

  • Demetri GD BR, Blanke CD et al (2004) NCCN task force report: optimal management of patient with gastrointestinal stromal tumor (GIST) – expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw 2(suppl 1):S1–S26

    Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    CAS  PubMed  Google Scholar 

  • Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H et al (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(suppl 2):S1–S29; quiz S30

    Google Scholar 

  • Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E et al (2005) BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24:3995–3998

    CAS  PubMed  Google Scholar 

  • Duffy MJ, Van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R et al (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348–1360

    CAS  PubMed  Google Scholar 

  • Fletcher JA, Corless C, Dimitrijevic S, von Mehren M, Eisenberg B, Joensuu H et al; for the GIST Working Group (2003) Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:815

    Google Scholar 

  • Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465

    PubMed  Google Scholar 

  • French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R et al (2008) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14:3408–3415

    CAS  PubMed  Google Scholar 

  • Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Trougouboff P, Tomsho LD et al (2003) Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 27:563–570

    PubMed  Google Scholar 

  • Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ et al (1999) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers [see comment]. J Natl Cancer Inst 91:1295–1303

    CAS  PubMed  Google Scholar 

  • Hartmann K, Wardelmann E, Ma Y, Merkelbach-Bruse S, Preussner LM, Woolery C et al (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129:1042–1046

    CAS  PubMed  Google Scholar 

  • Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003a) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349

    CAS  PubMed  Google Scholar 

  • Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al (2003b) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    CAS  PubMed  Google Scholar 

  • Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774

    CAS  PubMed  Google Scholar 

  • Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360–5367

    CAS  PubMed  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    CAS  PubMed  Google Scholar 

  • Hirota S, Okazaki T, Kitamura Y, O’Brien P, Kapusta L, Dardick I (2000) Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 24:326–327

    CAS  PubMed  Google Scholar 

  • Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A et al (2002) Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 122:1493–1499

    PubMed  Google Scholar 

  • Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125:660–667

    CAS  PubMed  Google Scholar 

  • Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M et al (2005) Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981–989

    CAS  PubMed  Google Scholar 

  • Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM (2000) Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 157:1581–1585

    CAS  PubMed  Google Scholar 

  • Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P et al (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer [see comment]. N Engl J Med 331:213–221

    CAS  PubMed  Google Scholar 

  • Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130–1136

    CAS  PubMed  Google Scholar 

  • Johnston PG, Benson AB III, Catalano P, Rao MS, O’Dwyer PJ, Allegra CJ et al (2003) Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21:815–819

    CAS  PubMed  Google Scholar 

  • Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J et al (2009) The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status [see comment]. Eur J Cancer 45:365–373

    CAS  PubMed  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer [see comment]. N Engl J Med 359:1757–1765

    CAS  PubMed  Google Scholar 

  • Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M, Nakamura Y et al (1989) Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected] [erratum appears in JAMA 1989 Oct 13;262(14):1952]. JAMA 261:3099–3103

    CAS  PubMed  Google Scholar 

  • Kim HJ, Lim SJ, Park K, Yuh YJ, Jang SJ, Choi J (2005) Multiple gastrointestinal stromal tumors with a germline c-kit mutation. Pathol Int 55:655–659

    CAS  PubMed  Google Scholar 

  • Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N et al (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study [see comment]. J Clin Oncol 25:767–772

    CAS  PubMed  Google Scholar 

  • Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269

    CAS  PubMed  Google Scholar 

  • Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y et al (2004) Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202:80–85

    CAS  PubMed  Google Scholar 

  • Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H et al (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85:790–798

    CAS  PubMed  Google Scholar 

  • Kluppel M, Huizinga JD, Malysz J, Bernstein A (1998) Developmental origin and Kit-dependent development of the interstitial cells of cajal in the mammalian small intestine. Dev Dyn 211:60–71

    CAS  PubMed  Google Scholar 

  • Lamberti C, Lundin S, Bogdanow M, Pagenstecher C, Friedrichs N, Buttner R et al (2007) Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis 22:145–152

    CAS  PubMed  Google Scholar 

  • Lasota J, Miettinen M (2006) A new familial GIST identified. Am J Surg Pathol 30:1342

    PubMed  Google Scholar 

  • Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M (1999) Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53–60

    CAS  PubMed  Google Scholar 

  • Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84:874–883

    CAS  PubMed  Google Scholar 

  • Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R et al (1998) p53 Point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250

    CAS  PubMed  Google Scholar 

  • Lievre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    CAS  PubMed  Google Scholar 

  • Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer [see comment]. J Clin Oncol 24:5313–5327

    CAS  PubMed  Google Scholar 

  • Ma Y, Cunningham M, Wang X, Ghosh I, Regan L, Longley B (1999) Inhibition of spontaneous receptor phosphorylation by residues in putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 274:13399–13402

    CAS  PubMed  Google Scholar 

  • Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A et al (2001) Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120:210–215

    CAS  PubMed  Google Scholar 

  • Maki R, Fletcher JA, Heinrich M et al (2005) Results from a continuation trial of SU11248 in patient (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 24:Abstract 9011

    Google Scholar 

  • Miettinen M, Monihan JM, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS et al (1999) Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 23:1109–1118

    CAS  PubMed  Google Scholar 

  • Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J (2000a) Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 24:211–222

    CAS  PubMed  Google Scholar 

  • Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J (2000b) Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 24:1339–1352

    CAS  PubMed  Google Scholar 

  • Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A et al (2003) Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 27:625–641

    PubMed  Google Scholar 

  • Miettinen M, Lasota J, Sobin LH (2005a) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29:1373–1381

    PubMed  Google Scholar 

  • Miettinen M, Sobin LH, Lasota J (2005b) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52–68

    PubMed  Google Scholar 

  • Miettinen M, Fetsch JF, Sobin LH, Lasota J (2006a) Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30:90–96

    PubMed  Google Scholar 

  • Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006b) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477–489

    PubMed  Google Scholar 

  • Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D et al (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59:3346–3351

    CAS  PubMed  Google Scholar 

  • Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655–31663

    CAS  PubMed  Google Scholar 

  • Nakatani H, Kobayashi M, Jin T, Taguchi T, Sugimoto T, Nakano T et al (2005) STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci 96:116–119

    CAS  PubMed  Google Scholar 

  • Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM (1992a) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215:68–77

    CAS  PubMed  Google Scholar 

  • Ng EH, Pollock RE, Romsdahl MM (1992b) Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 69:1334–1341

    CAS  PubMed  Google Scholar 

  • O’Riain C, Corless CL, Heinrich MC, Keegan D, Vioreanu M, Maguire D et al (2005) Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 29:1680–1683

    PubMed  Google Scholar 

  • Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J et al (2000) Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560–567

    CAS  PubMed  Google Scholar 

  • Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M (2003) Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine [see comment]. Cancer 97:1551–1557

    CAS  PubMed  Google Scholar 

  • Popat S, Houlston RS (2005) A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status, and colorectal cancer prognosis. Eur J Cancer 41: 2060–2070

    CAS  PubMed  Google Scholar 

  • Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22:529–536

    CAS  PubMed  Google Scholar 

  • Popat S, Zhao D, Chen Z, Pan H, Shao Y, Chandler I et al (2007) Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients [erratum appears in Anticancer Res 2007 Mar-Apr;27(2):1231]. Anticancer Res 27:627–633

    PubMed  Google Scholar 

  • Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM et al (2005) Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27:179–187

    PubMed  Google Scholar 

  • Ramon y Cajal S (1893) Sur les ganglions et plexus nerveux de l’intestin. Comp Rend Soc Biol Paris 45:217–223

    Google Scholar 

  • Reith JD, Goldblum JR, Lyles RH, Weiss SW (2000) Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 13:577–585

    CAS  PubMed  Google Scholar 

  • Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257

    CAS  PubMed  Google Scholar 

  • Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121

    CAS  PubMed  Google Scholar 

  • Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR et al (2005) A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 65:6631–6639

    CAS  PubMed  Google Scholar 

  • Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K (2001) Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 92:494–498

    CAS  PubMed  Google Scholar 

  • Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M et al (2001) Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level [see comment]. Cancer Epidemiol Biomarkers Prev 10:917–923

    CAS  PubMed  Google Scholar 

  • Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA et al (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer [see comment]. Gastroenterology 129:837–845

    CAS  PubMed  Google Scholar 

  • Sanders KM (1996) A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 111:492–515

    CAS  PubMed  Google Scholar 

  • Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V et al (2008) Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and stage III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26(suppl 15):Abstract #4008

    Google Scholar 

  • Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728–734

    CAS  PubMed  Google Scholar 

  • Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y et al (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104:18654–18659

    CAS  PubMed  Google Scholar 

  • Shiu MH, Farr GH, Papachristou DN, Hajdu SI (1982) Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 49:177–187

    CAS  PubMed  Google Scholar 

  • Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369–373

    CAS  PubMed  Google Scholar 

  • Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B et al (2006) Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131:729–737

    CAS  PubMed  Google Scholar 

  • Sommer G, Agosti V, Ehlers I et al (2003) Gastrointestinal stromal tumors in a mouse model by targeted mutations of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A 100:6706–6711

    CAS  PubMed  Google Scholar 

  • Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y et al (2005) Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen’s disease). Am J Surg Pathol 29:755–763

    PubMed  Google Scholar 

  • Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A et al (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294–299

    CAS  PubMed  Google Scholar 

  • Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK (2006) Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 66:5477–5486

    CAS  PubMed  Google Scholar 

  • Thuneberg L (1982) Interstitial cells of Cajal: intestinal pacemaker cells? Adv Anat Embryol Cell Biol 71:1–130

    CAS  PubMed  Google Scholar 

  • Tsao J-I, Shibata D (1994) Further evidence that one of the earliest alterations in colorectal carcinogenesis involves APC. Am J Pathol 145:531–534

    CAS  PubMed  Google Scholar 

  • Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054–5058

    CAS  PubMed  Google Scholar 

  • Tworek JA, Appelman HD, Singleton TP, Greenson JK (1997) Stromal tumors of the jejunum and ileum. Mod Pathol 10:200–209

    CAS  PubMed  Google Scholar 

  • Tworek JA, Goldblum JR, Weiss SW, Greenson JK, Appelman HD (1999a) Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. Am J Surg Pathol 23:937–945

    CAS  PubMed  Google Scholar 

  • Tworek JA, Goldblum JR, Weiss SW, Greenson JK, Appelman HD (1999b) Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. Am J Surg Pathol 23:946–954

    CAS  PubMed  Google Scholar 

  • Umar A, Boland R, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268

    CAS  PubMed  Google Scholar 

  • Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F et al (2009a) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal grown factor receptor 2 (HER2)-positive advanced gastric cancer. J Clin Oncol 27:Abstract LBA4509

    Google Scholar 

  • Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009b) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    PubMed  Google Scholar 

  • Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    CAS  PubMed  Google Scholar 

  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532

    CAS  PubMed  Google Scholar 

  • Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y et al (1989) Allelotype of colorectal carcinomas. Science 244:207–211

    CAS  PubMed  Google Scholar 

  • Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E et al (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106:887–895

    CAS  PubMed  Google Scholar 

  • Watanabe T, Tsung-Teh W, Catalano PJ, Ueki T, Satriano R, Haller DG et al (2001) Molecular predictors of survival after adjuvant therapy for colon cancer. N Engl J Med 344:1196–1206

    CAS  PubMed  Google Scholar 

  • Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer [see comment]. Nat Genet 38:787–793

    CAS  PubMed  Google Scholar 

  • Yantiss RK, Rosenberg AE, Sarran L, Besmer P, Antonescu CR (2005) Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol 18:475–484

    CAS  PubMed  Google Scholar 

  • Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E et al (2001) Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 61:2676–2683

    CAS  PubMed  Google Scholar 

  • Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L (1997) Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125–2131

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Vanderbilt University Medical Center, C-3321 MCN, Nashville, TN, 37232, USA

    Kay Washington

  2. Department of Pathology, Oregon Health & Science University and Knight Cancer Institute, Portland, OR, USA

    Christopher L. Corless

Authors
  1. Kay Washington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher L. Corless
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kay Washington .

Editor information

Editors and Affiliations

  1. Div. Medical Oncology, University of British Columbia, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    Charles D. Blanke

  2. FB 19 Zentrum der Radiologie, Klinik f. Strahlentherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany

    Claus Rödel

  3. Evanston Northwestern Healthcare, Northwestern University, Ridge Ave. 2650, Evanston, 60201, Illinois, USA

    Mark S. Talamonti

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Washington, K., Corless, C.L. (2011). Practical Gastrointestinal Oncology Correlative Science. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13306-0_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13305-3

  • Online ISBN: 978-3-642-13306-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation